RxBio was formed around novel and proprietary small-molecule technology developed at the University of Tennessee Health Science Center (UTHSC) in Memphis and licensed from the University of Tennessee Research Foundation (UTRF). RxBio's technology platform is broadly based and includes includes its lead compoun, Rx100. Recent murine and nonhuman primate studies (required under FDAâs âAnimal Ruleâ for demonstration of safety and efficacy) have confirmed Rx100âs ability to dramatically improve survival after high doses of irradiation. The company also is working on treatment of secretory diarrhea, prevention of NSAID-induced stomach erosions (e.g., aspirin), compounds for treatment and prevention of hematological-ARS, anti-inflammatory compounds, a compound for treatment of glioma â a universally fatal form of brain cancer RxBio Holdings, Inc. operates as a biotechnology company developing products that protect against lethal whole-body radiation, and against damage to the GI tract due to radiation, chemotherapy and various toxins. The company develops cancer agents and those that block plaque build-up in blood
